A Comparison Study of Hypersensitivity Treatment

NCT05768373 | Completed Results FDA Device

• 1 other identifier: EM-11-050084
• Study Type: interventional
• Target: 101
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate the effect of 3M™ Clinpro™ Fluoride Aqueous Solution (experimental) on Dentin Hypersensitivity (DHS) in comparison to 3M™ Vanish™ (commercialized, control\] in patients who have DHS. Participants will be asked to complete the following activities: Undergo a pre-treatment washout period for 3- to 6-weeks (± 4 days) post-enrollment. During this time, the Subject is to only use the provided oral hygiene products. Hypersensitivity will be assessed prior to (baseline) and immediately after sample application. Subject will be asked to come to the facility for hypersensitivity assessments at 24 hours, 7 days, and 30 days after the treatment visit. Researchers will compare 3M™ Clinpro™ Fluoride Aqueous Solution to 3M™ Vanish™ to evaluate if the effect of Clinpro™ on DHS treatment is non-inferior to Vanish™.

Conditions

Dentin Hypersensitivity

Outcome Measures

Primary Outcomes (2)

• Change in Pain From Baseline Immediately After Application of Test Product.

  Change in sensitivity as assessed using a Visual Analog Scale (VAS, 0 - 100 mm) immediately after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.

  Base line and immediately after application (within 15 minutes post-treatment).

• Change in Pain From Baseline 24 Hours Post Application of Test Product.

  This is a co-primary endpoint Change in sensitivity as assessed using 100-mm Visual Analog Score (VAS) 24 hours after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.

  Baseline and 24 hours post-treatment

Secondary Outcomes (3)

• Change in Pain From Baseline 7 Days Post Application of Test Product.

  Baseline and 7 days post-treatment

• Change in Pain From Baseline 21 Days Post Application of Test Product.

  Baseline and 21 days post-treatment

• Change in Pain From Baseline 30 Days Post Application of Test Product.

  Baseline and 30 days post-treatment

Study Arms (2)

3M™ Clinpro™ Fluoride Aqueous Solution

EXPERIMENTAL

Investigational product.

Device: 3M™ Clinpro™ Fluoride Aqueous Solution

3M™ Vanish™

ACTIVE COMPARATOR

Commercialized product

Device: 3M™ Vanish™

Interventions

3M™ Clinpro™ Fluoride Aqueous Solution DEVICE

Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.

3M™ Clinpro™ Fluoride Aqueous Solution

3M™ Vanish™ DEVICE

Hypersensitivity treatment. Apply once after baseline measurement of dentin sensitivity.

3M™ Vanish™

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject has at least one affected hypersensitive tooth upon air blast stimuli in the cervical area, and baseline pain score of 40 mm and above as assessed by the 100 mm VAS.
• Subject is at least 18 years old and have a minimum of 20 natural teeth.
• Subject is willing to withhold desensitizing treatment, including prescription, in-office or over the counter (OTC) desensitizing products, throughout the study period AND withhold during the washout period.
• Subject agrees to only use the provided toothpaste, toothbrush, and follows all oral hygiene instructions throughout the study period AND follows all oral hygiene instructions during the washout period.
• Subject is able to understand and willing to sign the Informed Consent, and is willing to return to the study facility for scheduled study visits and recalls.

You may not qualify if:

• Subject has medical (including psychiatric) and pharmacotherapeutic histories that may compromise the protocol - including the chronic use of anti-inflammatory, analgesic (pain), and mind-altering drugs; or analgesic (pain) medications within 48 hours prior to application of treatment.
• Subject is pregnant (self-reported) or breast feeding.
• Subject has allergies to product ingredients, eg, rosin, mint flavoring.
• Subject has systemic conditions that are etiologic or predisposing to dentin hypersensitivity (eg, chronic acid regurgitation).
• Subject has excessive dietary or environmental exposure to acids at time of screening.
• Subject had periodontal treatment, bleaching treatments, or orthodontic treatments within previous 3 months or plans to have any other dental treatments during the study period.
• Subject is enrolled in another clinical trial at the time of screening that would interfere with this study.
• Individual teeth may not be included that meet any of the following criteria:
• Study tooth has periodontal probing depth of ≥ 4 mm.
• Study tooth or the surrounding supporting tissue has any other painful pathology or defects.
• Study tooth has been restored in the preceding 3 months.
• Study tooth is an abutment for fixed or removable prostheses or suffers traumatic malocclusion.
• Study tooth is crowned or extensively restored and the restorations extending into the test area.
• The tooth has dentin hypersensitivity due to cracked enamel.

Sponsors & Collaborators

• Solventum US LLC: lead

Study Sites (1)

LOMA LINDA UNIVERSITY, School of Dentistry

Loma Linda, California, 92350, United States

Location

MeSH Terms

Conditions

Dentin Sensitivity

Condition Hierarchy (Ancestors)

Tooth Diseases; Stomatognathic Diseases

Results Point of Contact

• Title: Helen Han
• Organization: Solventum

mhan3@solventum.com

6517856568

Study Officials

• Yiming Li

  Loma Linda University, School of Dentistry

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Masking Details: Only subject will be blinded.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 1, 2023
• First Posted: March 14, 2023
• Study Start: April 4, 2023
• Primary Completion: July 14, 2023
• Study Completion: July 14, 2023
• Last Updated: February 7, 2025
• Results First Posted: February 7, 2025

Record last verified: 2025-01

Locations

US (1)